← Back to Search

Collagenase

Single-Arm for Peyronie's Disease

Phase 4
Waitlist Available
Led By Jed Kaminetsky, MD
Research Sponsored by Manhattan Medical Research Practice, PLLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from screening up to 24 weeks
Awards & highlights

Study Summary

Subjects who have had an incomplete response to previous Xiaflex® will receive up to 4 additional cycles of treatment.

Eligible Conditions
  • Peyronie's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from screening up to 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and from screening up to 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in the degree of penile curvature

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single-ArmExperimental Treatment1 Intervention
Xiaflex® 0.58 mg, 2 injections separated by 1 to 3 days, repeated after 6 weeks for up to 4 treatment cycles.

Find a Location

Who is running the clinical trial?

Endo PharmaceuticalsIndustry Sponsor
133 Previous Clinical Trials
33,135 Total Patients Enrolled
12 Trials studying Peyronie's Disease
1,925 Patients Enrolled for Peyronie's Disease
Manhattan Medical Research Practice, PLLCLead Sponsor
Jed Kaminetsky, MDPrincipal InvestigatorPrincipal Investigator
2 Previous Clinical Trials
216 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
New Jersey
What site did they apply to?
Manhattan Medical Research Practice, PLLC
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response
2018. "Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03767452.
All > Peyronies Disease
~3 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top